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Abstract 
Chronic liver disease is a process that involves progressive destruction and regeneration 
of the liver causing fibrosis, cirrhosis and hepatocellular carcinoma, and early death.  Persons 
with chronic liver disease treated for hepatitis C with abnormal radiological imaging consistent 
with increased fat content in the liver (hepatic steatosis) should be evaluated for nonalcoholic 
fatty liver disease (NAFLD).  However, individuals treated at a community hepatitis C treatment 
clinic are currently not being evaluated for NAFLD.  In addition, if NAFLD is diagnosed, 
management of these co-occurring conditions is required to delay disease progression.  Factors 
contributing to gaps in NAFLD care include: poor communication, incomplete transfer of 
information, inadequate education of patients, and the absence of a single point person to ensure 
continuity of care.   
This Doctor of Nursing Practice (DNP) project involved the development and 
implementation of a protocol with person-centered education to assure continuity of care based 
on need of those with chronic liver disease, hepatitis C and NAFLD.  Findings after the 
implementation and evaluation of the process improvement protocol at the clinic noted patients 
being treated for hepatitis C with hepatic steatosis: 1) were systematically evaluated for and 
diagnosed with NAFLD during treatment of hepatitis C infection at the clinic; 2) received 
NAFLD person-centered education; and 3) transitioned from specialty care after completion of 
hepatitis C infection treatment to primary care provider for ongoing NAFLD management. 
Keywords: hepatic steatosis, nonalcoholic fatty liver disease, hepatitis C, transition of care 
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Executive Summary 
Chronic liver disease can alter normal liver function leading to fibrosis, cirrhosis, 
hepatocellular carcinoma, and early death (Kyungeh et al., 2015).  Chronic liver disease is one of 
the ten leading causes of death worldwide effecting people of all ages, particularly, those 40 to 
60 years of age (National Institute of Health, 2009).  Two major causes of chronic liver disease 
are chronic hepatitis C infection and nonalcoholic fatty liver disease (Kyungeh et al., 2015).  
Nonalcoholic fatty liver disease (NAFLD) involves a spectrum of liver diseases that range from 
fatty infiltration of the liver (hepatic steatosis), to liver inflammation (nonalcoholic 
steatohepatitis [NASH]), leading to fibrosis and/or cirrhosis (McCarthy & Rinella, 2012).  The 
Center for Disease Control’s National Vital Statistics Reports, Deaths: Final Report for 2013 
(Xu, Murphy, Kochanek & Bastian, 2016) reported chronic liver diseases and cirrhosis as a 
leading cause of death in the United States (US).  Xu et al. (2016) reported in 2013, US deaths 
caused by nonalcoholic related chronic liver disease and cirrhosis totaled 18,281 and malignant 
neoplasms of liver and intrahepatic bile ducts was 24,032.   
In a clinic setting, 30% to 70% of patients with hepatitis C have hepatic steatosis 
(Blonsky & Harrison, 2008; Patel & Harrison, 2012; Rafiq & Younossi, 2008).  An 
organizational assessment of a Midwestern hospital’s clinic revealed a need for individuals with 
hepatitis C treated at their clinic to be further evaluated for NAFLD.  Records of 100 patients at 
the clinic revealed 34 (34%) of the patients that received treatment for hepatitis C infection had 
hepatic steatosis noted on radiological imaging that needed further evaluation. 
Clinical practice guidelines for diagnosis and management of NAFLD recommend 
patients at the clinic with hepatitis C who have abnormal imaging consistent with hepatic 
steatosis should be evaluated for NAFLD (Chalasani et al., 2012).  If NAFLD was diagnosed in 
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patients at the clinic, management of these co-occurring conditions was required to delay disease 
progression.  These patients required patient education and transition of care to their PCP after 
treatment of hepatitis C infection was completed for ongoing NAFLD management.   
The intent of the DNP student’s quality improvement project was to improve the care for 
patients treated for hepatitis C with hepatic steatosis at the clinic through the development and 
implementation of a process improvement protocol.  Findings after the implementation and 
evaluation of the process improvement protocol at the clinic noted patients being treated for 
hepatitis C with hepatic steatosis: 1) were systematically evaluated for and diagnosed with 
NAFLD during treatment of hepatitis C infection at the clinic; 2) received NAFLD person-
centered education; and 3) transitioned from specialty care after completion of hepatitis C 
infection treatment to primary care provider for ongoing NAFLD management. 
This DNP student’s quality improvement project may be useful for clinical practice in 
other primary and specialty practice settings, to diagnose and manage patients with NAFLD, and 
improve patient care transitions.  Health care providers are key in early identification of NAFLD 
for treatment not only in patients with hepatitis C, but other patients with risk factors for 
NAFLD, such as obesity and type 2 diabetes.  Early identification of NAFLD and treatment 
could prevent the development of nonalcoholic steatohepatitis, cirrhosis, liver failure and 
possibly hepatocellular carcinoma (Loomba & Sanyal, 2013).   
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Introduction 
Chronic liver disease is one of the ten leading causes of death worldwide effecting people 
of all ages, particularly, those 40 to 60 years of age (National Institute of Health, 2009).  Chronic 
liver disease can alter normal liver function leading to fibrosis, cirrhosis, hepatocellular 
carcinoma, and early death (Kyungeh et al., 2015).  Two major causes of chronic liver disease 
are chronic hepatitis C infection and nonalcoholic fatty liver disease (Kyungeh et al., 2015).   
Hepatitis C infection is a viral, and contagious liver disease spread through contact with 
the blood of an infected person (Center for Disease Control [CDC], 2015).  Approximately 2.7 
million persons in the United States (US) are infected with hepatitis C virus (CDC, 2015).  
Nonalcoholic fatty liver disease (NAFLD) involves a spectrum of liver diseases that range from 
fatty infiltration of the liver (hepatic steatosis), to liver inflammation (nonalcoholic 
steatohepatitis [NASH]), leading to fibrosis and/or cirrhosis (McCarthy & Rinella, 2012).  
NAFLD is one of the most common causes of chronic liver disease, affecting nearly 70 million 
adults in the US (Loomba & Sanyal, 2013; McCarthy & Rinella, 2012).   
Nearly 70% of patients with hepatitis C infection have hepatic steatosis (Blonsky & 
Harrison, 2008; Patel & Harrison, 2012; Rafiq & Younossi, 2008) as a result of a virus genotype 
such as hepatitis C – Genotype 3 or from metabolic conditions such as insulin resistance, 
diabetes mellitus or metabolic syndrome (Adinolfi, Durante-Mangoni, Zampino, Ruggier, 2005; 
Leandro et al., 2004).   As a consequence, coexisting NAFLD and hepatitis C increases chronic 
liver disease progression, elevates risk of hepatocellular carcinoma, and decreases the response 
to antiviral therapy treatment (Cortez-Pinto & Machado, 2010; Sanyal et al., 2010; & Watanbe et 
al., 2008).  The focus of this Doctor of Nursing Practice (DNP) scholarly project is on facilitating 
assessment, timely diagnosis and appropriate treatment of NAFLD, with appropriate transition to 
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primary care for patients with hepatitis C infection and comorbid hepatic steatosis in a 
Midwestern clinic. 
Background 
Overview                                                                                                                     
 Patients with hepatitis C and NAFLD often require treatment to prevent liver disease 
progression.  Clinical practice guidelines for the management of hepatitis C and NAFLD are 
available (American Association for the Study of Liver Disease & Infectious Diseases Society of 
America, 2015; Chalasani et al., 2012).  However, there are no known clinical practice 
guidelines for the comorbid conditions of hepatitis C when NAFLD is present.  Thus, there is a 
great need to focus on diagnosis and treatment of fatty liver disease, namely NAFLD (Balisteri, 
2014).   
Literature Supporting Problem 
Nonalcoholic fatty liver disease (NAFLD) progression to nonalcoholic steatohepatitis 
(NASH), was first described by Ludwig, Viggiano, McGill & Ott (1980).  Nonalcoholic fatty 
liver disease is now recognized as one of the most common causes of chronic liver disease, 
affecting nearly 70 million adults in the US (Loomba & Sanyal, 2013; McCarthy & Rinella, 
2012).  Nonalcoholic fatty liver disease is a spectrum of liver diseases that range from simple 
fatty infiltration of the liver (steatosis) to fat infiltration with liver inflammation (known as 
NASH); to cirrhosis (McCarthy & Rinella, 2012).   
The diagnosis of NAFLD requires evidence of hepatic steatosis, either by imaging or by 
histology, not caused by secondary hepatic fat accumulation such from alcohol consumption, use 
of steatogenic medication, or hereditary disorders (Chalasani et al., 2012).  Individuals with 
persistently abnormal aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 
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levels; or with an abnormal hepatic imaging consistent with increased fat content in the liver, 
should be evaluated for NAFLD (Attar and Van Thiel, 2012).  It is essential for healthcare 
providers to understand the complexity of NAFLD.  A survey of 246 providers to assess 
understanding and practice patterns of primary care providers with respect to the diagnosis and 
management of NAFLD found the majority of providers did not identify NAFLD as a clinically 
important diagnosis (Wieland et al., 2013).   
The National Health and Nutrition Examination Survey data from 1988 to 2008 found the 
prevalence of major causes of chronic liver disease remained unchanged, with the exception of 
NAFLD and metabolic conditions, which both increased (Younossi et al., 2011).  Given the 
increasing rates of obesity in the US, NAFLD is expected to contribute substantially to the 
burden of chronic liver disease (Younossi et al., 2011).  This is of grave concern because 
NAFLD left untreated can lead to the development of NASH in approximately 25 percent of 
patients (Temple et al., 2016 & Watanabe et al., 2008). 
Nonalcoholic steatohepatitis (NASH) is a progressive form of NAFLD that can lead to 
cirrhosis and potentially hepatocellular carcinoma (HCC), necessitating liver transplantation, and 
often contributes to liver-related mortality (Loomba & Sanyal, 2013; Wong, Cheung, & Ahmed, 
2014).  Cirrhosis is a chronic degenerative disease in which normal liver cells are damaged and 
replaced by scar tissue (fibrosis) and nodules (Ferri, 2009).   Hepatocellular (HCC) is a 
malignant tumor of the hepatocytes (Ferri, 2009).  Transplantation data in the US from 2002 to 
2012 showed the incidence of NASH among HCC patients has increased dramatically, and could 
become the top indicator for liver transplantation (Wong et al., 2014).  Therefore, identification 
of ways to diagnose and manage NAFLD are needed. 
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Gaps in patient care outcomes.  The DNP prepared nurse practitioner working at the 
Midwestern hepatitis C clinic, receives patient referrals from primary care for the treatment of 
hepatitis C infection.  The clinic’s DNP prepared nurse practitioner saw 330 patient referrals 
from primary care for evaluation and treatment of hepatitis C infection in 2015.  A chart review 
was conducted in the clinic to determine prevalence of hepatic steatosis noted on radiological 
imaging, among patients with hepatitis C.  Records of 100 patients were randomly selected by 
the DNP prepared nurse practitioner and radiological imaging reports were reviewed for the 
presence of hepatic steatosis.  There were 34 (34%) radiological imaging reports that noted the 
presence of hepatic steatosis; while 66 (66%) had no evidence of hepatic steatosis.  
Consequently, 34% of the patients with comorbid hepatitis C had hepatic steatosis at the clinic.  
This is consistent with the rate of occurrence of hepatic steatosis in those with hepatitis C, 
reported in the literature (Blonsky & Harrison, 2008; Patel & Harrison, 2012; Rafiq & Younossi, 
2008).   
 From this chart audit and conversations with team members at the clinic, two gaps in care 
were identified among patients with hepatitis C who have hepatic steatosis on radiological 
imaging in the clinic.  First, a thorough assessment is lacking in those with hepatic steatosis to 
determine if NAFLD is present.  Second, if diagnosed with NAFLD, no transition in care to the 
primary care provider (PCP) is occurring after treatment of hepatitis C in the clinic is complete.  
At this time, the clinic focuses on their primary purpose, treatment of hepatitis C infection; 
leaving NAFLD undiagnosed.  Timely assessment and diagnosis of NAFLD in patients with 
hepatitis C could potentially prevent liver disease progression (Loomba & Sanyal, 2013).   
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Problem Statement  
 The problem addressed in this scholarly project is: Would a protocol to address 
assessment of NAFLD, and provision of patient education and transition in care to a PCP if 
diagnosed, improve the quality of care for patients with hepatitis C who have hepatic steatosis?  
A protocol could guide the clinicians in the clinic in the following ways: (1) identification and 
diagnosis of NAFLD; (2) if diagnosed with NAFLD, provision of patient education about the 
disease by the DNP prepared nurse practitioner in the clinic at the end of their hepatitis C 
treatment; and (3) a transition plan to the PCP for ongoing management of NAFLD.  In the next 
section, a summary of the organizational assessment will be presented.  
Organizational Assessment 
 An organizational assessment was conducted to inform this scholarly project.  An 
assessment identifies an organization’s strengths and weaknesses, and pinpoints areas needing 
improvement (Canadian International Developmental Agency [CIDA], 2006).   
Setting 
The setting for this scholarly project was a Midwestern hepatitis C clinic.  The clinic is a 
component of a regional health system.  
Population and Sample 
The population of interest in this scholarly project were patients diagnosed with hepatitis 
C infection and comorbid hepatic steatosis.  The sample included patients diagnosed with 
hepatitis C infection who had hepatic steatosis reported on radiological imaging at the clinic.  
The number of patients receiving treatment for hepatitis C with hepatic steatosis who 
require evaluation of NAFLD varied by the number of referral patients from PCPs to the clinic.  
In a clinic setting it is estimated that at least 30 to 70 percent of patients will have hepatitis C and 
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NAFLD type hepatic steatosis (Blonsky & Harrison, 2008; Patel & Harrison, 2012; Rafiq & 
Younossi, 2008).  During three months (April, May, and June of 2016), the average number of 
patient referrals for treatment of hepatitis C at the clinic was 20, and approximately seven or 30 
percent of these patients will potentially have hepatic steatosis.   
Framework to Assess the Organization 
An organizational assessment was conducted of the clinic using the 2006 Canadian 
International Developmental Agency (CIDA) Organization Assessment Guide.  The CIDA 
Organization Assessment Guide (2006) was designed by the Canadian International 
Development Agency Evaluation Division Performance and Knowledge Management Branch; 
and by Universalia, an international consulting firm.  The CIDA approach (Appendix A) to 
organization assessment included an examination of the following elements: 1) organizational 
performance, 2) organizational motivation, 3) organizational capacity, and 4) the external 
environment (CIDA, 2006).  This tool was chosen as it provides a framework to assess strengths, 
weaknesses and opportunity for improvement at the clinic (CIDA, 2006).   
Organization performance.  The effectiveness of an organization in achieving their 
mission depends on its ability to adapt to a changing environment and generate revenues to meet 
its functional requirements for sustainability (CIDA, 2006).  An organization assessment was 
conducted on the clinic, to include the mission, finances, and services provided to the public. 
The clinic is a component of a large nonprofit organization and operates for public 
benefit.  This nonprofit organization is a regional referral hospital system for the geographic 
area.  It is the largest health system in the geographic area and the largest employer in the region.  
The clinic is a component of the regional health system, thus, the clinicians are employees of this 
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organization.  The clinic is supported by revenue from health care services provided to patients 
for treatment of hepatitis C infection.   
Organization motivation.  Organizational motivation, or work climate, represents 
beliefs, values, and norms that guide work life within an organization (CIDA, 2006).  An 
assessment was conducted of the organization and the clinic, to include culture, mission, and 
values.   
As a nonprofit organization, this organization is committed to public service, serving and 
meeting the needs of citizens, and strengthening the community.  The clinic and clinician team 
are dedicated to treating patients with hepatitis C infection.  A former DNP student, who is now 
a current practitioner and employee, was instrumental in the establishment of the clinic.  The 
clinic provided specialty patient-centered, personalized care for those diagnosed with hepatitis C 
infection.  At the time of the assessment, the clinic did not coordinate specialty services and care 
management for patients with hepatitis C who had been diagnosed with comorbid hepatic 
steatosis. 
External environment.  Organizations exist within external environments that facilitate 
or impede performance (CIDA, 2006).  The clinic is located in a county with a population of 
172,188 (Community Research Institute [CRI], 2015).  The largest age group for this county is 
the 45 to 64 years old (27.7%), with gender distribution of 50.4% female and 49.6% male, and a 
racial mix of 77.3% White, 14.3% African American, and 8.4% other (CRI, 2015).   
People between the ages of 51 to 71 years old make up the majority of chronic hepatitis C 
cases (CDC, 2015).  National data demonstrate that people in this age group are five times more 
likely than other adults to be infected with hepatitis C (CDC, 2015).  In addition, people between 
the ages of 51 and 71 years old account for 73% of all hepatitis C associated mortality (CDC, 
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2015).  This CDC information is important because the county had a large percentage of its 
population in this age group who may require hepatitis C screening and treatment. 
 The rate of poverty in the county is 18.6%, higher than the state rate of 16.1%; and the 
US rate of 14.3% (PHMC, n.d.).  Nearly 12% of the population in this county who are less than 
65 years of age are uninsured (PHMC, n.d.).  The uninsured rate is important because there is a 
cost of up to $1000.00 a day for hepatitis C infection medications such as ledipasvir-sofosbuvir 
(Hepatitis C Online, 2016).  Patients without insurance may need a pharmaceutical company 
assistance program if they cannot afford to pay for these medications.   
In 2010, Michigan had the 6th highest prevalence of obesity in the US (MDCH, 2013).  
An estimated 31.7% of Michigan adults were obese, while approximately 35.1% of adults were 
overweight (MDCH, 2013).  The county is one of the most obese counties in the state, with 36% 
of residents being obese (PHMC, n.d.).  Obesity is a risk factor for NAFLD and other medical 
conditions such as type 2 diabetes and dyslipidemia.   
Organization capacity.  Organizational capacity exists in leadership, human resources, 
resources and partnerships (CIDA, 2006).  The organization has a local board; executive, senior, 
and physician leadership teams; and several medical staff officers.  The senior leadership team 
had a chief nursing officer, vice president of patient care services, and a patient safety officer.  
The clinic is part of this larger formal organization structure.  
The clinic is unique in that it is the only location in the city that treats hepatitis C 
infection.  The clinic opened in 2011 as a result of a DNP scholarly project, as mentioned earlier, 
in collaboration with an infectious disease physician, to provide treatment for underserved 
patients with hepatitis C infection.  In 2012, the organization hired the DNP prepared nurse 
practitioner as a part time employee (24 hours per week) to provide treatment for patients with 
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hepatitis C infection.  In 2013, as the number of patient referrals increased, the clinic required 
additional staff, and a part time (8 hours per week) pharmacist was hired.  The pharmacist 
assisted the DNP prepared nurse practitioner with medication management and insurance 
approval of medications.  The DNP prepared nurse practitioner collaborated with the clinic 
physician and reported to the nursing director on operations of the clinic.  In 2014, the referrals 
continued to increase leading to the hiring of a 32 hours per week Bachelor of Science prepared 
registered nurse (RN) case manager for the clinic.  The DNP prepared nurse practitioner work 
hours were also increased to 32 hours per week.  A medical assistant was hired in 2016 to assist 
the RN case manager.  Paper records are used for patient care, as there is no electronic health 
record available.  
The clinic team members obtained the Fibroscan 502 Touch (Echosens) at the clinic in 
May of 2016, after the initial organizational assessment.  The clinic team members received 
training on how to use the Fibroscan 502 Touch (Echosens) and began using it on referral 
patients for evaluation of fibrosis.  Sasso et al. (2010) reported the Fibroscan is an ultrasound-
based vibration-controlled transient elastography device used to assess liver stiffness related to 
fibrosis.  Ledinghen et al. (2014) reported a method for non-invasive assessment of hepatic 
steatosis with liver stiffness is controlled attenuation parameter (CAP) evaluated with transient 
elastography. The Fibroscan 502 Touch (Echosens) provides an immediate non-invasive 
evaluation of hepatic steatosis and liver fibrosis for patients with chronic liver disease such as 
hepatitis C and NAFLD.  The DNP prepared nurse practitioner plans to use the Fibroscan 502 
Touch (Echosens) technology to evaluate for hepatic steatosis and fibrosis in all new patients 
referred to the clinic for treatment of hepatitis C infection.  Early diagnosis of NAFLD and 
management can potentially delay disease progression.   
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Stakeholders.  A stakeholder is a person or group that has interest in an organization.  
The clinic stakeholders included the DNP prepared nurse practitioner, RN case manager, medical 
assistant, and pharmacist who were team members of the clinic providing patient care.  Patients 
with hepatitis C receiving treatment at the clinic who needed further evaluation of hepatic 
steatosis were stakeholders, as well as the referring primary care physician (PCP) who would be 
assuming care of patients diagnosed with NAFLD.   
Analysis of the assessment.  This organization is a financially viable nonprofit 
organization whose mission and core values are to advocate for and serve the poor and 
vulnerable in their communities.  This organization is committed to public service, serving and 
meeting the needs of citizens, and strengthening the community.  This organization is dedicated 
to meeting the healthcare needs of residents in the community they serve. 
Residents of the county utilize this organization for their healthcare needs.  Residents in 
need of hepatitis C infection treatment use the highly assessable clinic at the campus location.  
This organization chose to meet a community need and supported the establishment of the clinic 
in 2012.  The clinic continues to provide services to residents diagnosed with hepatitis C 
infection.  The clinic has dedicated and compassionate providers and staff who care for patients 
with hepatitis C infection.  The DNP prepared nurse practitioner recognized an additional need 
for patients receiving treatment for hepatitis C infection who have comorbid hepatic steatosis.   
The organization’s needs.  New cases of hepatitis C infection continue to be reported in 
the county (PHMC, 2015).  Primary care providers (PCPs) are screening for hepatitis C infection 
and making referrals to the clinic for evaluation and treatment.  The clinic is providing critically 
needed services for patients with hepatitis C infection.    
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The DNP prepared nurse practitioner identified a patient health care need at the clinic.  
As some hepatitis C patients have hepatic steatosis on radiological imaging, there was a need to 
evaluate for the presence of NAFLD.  If a diagnosis of NAFLD was found, these patients 
required transition of care to their PCP after treatment of hepatitis C infection was completed, for 
ongoing NAFLD management.  The next section presents a review of the evidence supporting 
why there was a need to address this critical problem. 
The Evidence-Based Project 
Evidence Supporting the Evidence-Based Project Solution  
It may be possible for hepatitis C to be cured with direct-acting antiviral agent medication 
use, resulting in a decrease in HCC.  This decrease in HCC has great significance, as it can lead 
to a reduction in the need for liver transplantation for cancer caused by hepatitis C infection 
disease progression (Wong et al., 2014).   
It is also known that hepatitis C infection can progress to cirrhosis and increased HCC 
(The American Association for the Study of Liver Diseases [AASLD] & Infectious Diseases 
Society of America [IDSA], 2015).  However, progression can be prevented with earlier 
intervention and treatment of the hepatitis C infection (AASLD & IDSA, 2015).  To provide 
healthcare professionals with guidance on how to treat their patients with hepatitis C infection, 
the American Association for the Study of Liver Diseases and the Infectious Diseases Society of 
America (2015) developed a web-based process at http://www.hcvguidelines.org/ for evidence-
based recommendations for hepatitis C management.      
The American Association for the Study of Liver Diseases, jointly with the American 
College of Gastroenterology and the American Gastroenterological Association, published 
guidelines in 2012 for the diagnosis and management of NAFLD (Chalasani et al., 2012).  These 
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guidelines recommend hepatic steatosis, either by imaging or by histology and there are no 
causes for secondary hepatic fat accumulation such as significant alcohol consumption, use of 
steatogenic medication, or hereditary disorders for the diagnosis of NAFLD (Chalasani et al., 
2012).  NAFLD is often found incidentally when a patient has elevated liver enzymes or when 
the disease is seen on radiologic imaging.   
Clinical practice guidelines for NAFLD recommend that patients with unsuspected 
hepatic steatosis detected by imaging should be evaluated as though they have NAFLD 
(Chalasani et al., 2012).  Further, clinical practice guidelines for NAFLD recommend that 
patients who have signs attributable to liver disease, or have abnormal liver biochemistries 
should be evaluated as though they have suspected NAFLD (Chalasani et al., 2012).  When 
hepatic steatosis is evident in patients with other chronic liver disease, such as in hepatitis C, it is 
important to assess patients for metabolic risk factors to include significant alcohol consumption, 
use of steatogenic medication, or hereditary disorders (Chalasani et al., 2012).    
The goal of NAFLD treatment includes prevention or reversal of hepatic injury and 
fibrosis through diet and exercise for weight loss and management of diabetes and dyslipidemia 
(Schwenger & Aller, 2014; Wilkins et al., 2013).  Application of these guidelines for early 
identification and treatment of NAFLD could help prevent the development of cirrhosis in 
patients diagnosed with hepatitis C who have hepatic steatosis (Loomba & Sanyal, 2013).   
Primary care providers may not be using the established American Association for the 
Study of Liver Diseases guidelines for diagnosis and management of NAFLD (Bergqvist et al., 
2012; Wieland et al., 2013).  Researchers using surveys to assess understanding and practice 
patterns of PCPs with respect to the diagnosis and management of NAFLD reported the majority 
of providers did not identify NAFLD as a clinically important diagnosis and do not refer to 
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hepatology specialty care providers (Bergqvist et al., 2012; Wieland et al., 2013).  It is essential 
for PCPs to understand the complexity of NAFLD in order to identify risk factors, evaluate for 
and diagnose the disease.  One opportunity to address this problem is to utilize targeted 
education for PCPs on the diagnosis and management of NAFLD (Bergqvist et al., 2012; 
Wieland et al., 2013).  Another method for increasing awareness and knowledge about the 
management of NAFLD is communication and collaboration between providers during the 
transition of patient care from specialty care provider to PCP (Naylor & Keating, 2008; Rooney 
& Arbaje, 2013).   
Feasibility of Project to Improve Organization  
The DNP prepared nurse practitioner currently working in the clinic requested assistance 
with establishing a protocol to provide care for patients with hepatitis C who were not being 
diagnosed for NAFLD.  The clinic members were willing to incorporate the protocol into routine 
care for patients, in order to better meet patient needs, based on known evidence and practice 
guidelines.   
Potential barriers.  There were several potential barriers identified that did not prohibit 
the project success: 1) there is only one DNP prepared nurse practitioner at the clinic, therefore, 
patient care cannot occur when she is not available; 2) the clinic uses paper health records for 
sharing of patient health information from the DNP prepared nurse practitioner to the PCPs; 3) 
communication among providers is often delayed without a shared electronic health record; and 
4) communication between providers via fax or mail can be misplaced or not reviewed; and may 
not be scanned into the electronic health record impacting patient care transitions.   
The clinic members implemented the protocol to better meet the needs of the patient, 
with potential barriers to the implementation of the protocol identified.  Initiatives to change 
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practice patterns are often guided by conceptual models.  Two conceptual models, the 
Transitional Care Model and the Plan-Do-Study-Act Cycle were used to guide change in clinical 
practice patterns.  
Conceptual Models Guiding Project 
Framework Guiding Evidence-Based Initiative: Transitional Care Model  
The Transitional Care Model (TCM, 2014) (Appendix B), designed by Naylor and 
colleagues at the University of Pennsylvania, guided this scholarly project.  Transitions in care 
are services designed to ensure healthcare continuity, avoid preventable poor outcomes, and 
promote the safe and timely transfer of patients from one type of setting to another (Naylor et al., 
2011).  The Transitional Care Model (TCM) is a nurse-led, team-based care delivery system 
approach designed to increase alignment of the care system with the individual and achieve 
higher-quality outcomes (Naylor, 2012).  The TCM addresses the negative effects associated 
with the care of older adults as they transition from one healthcare setting to another through 
patient engagement, shared decision-making, shared accountability, and self-management 
(Naylor, et al., 2013).  The TCM can also be used in a primary care setting such as the patient-
centered medical homes (Naylor, et al., 2013).  Further, use of TCM supports patient and 
healthcare team members working together to identify needs and preferences, and to implement 
care plans designed to improve health and quality of life (Naylor, 2012).   
Care coordination has been identified by the 2001 Institute of Medicine report as one of 
20 national priorities for action.  Rooney and Arbaje (2013) report poorly coordinated care or 
transition of care makes patients responsible for their own health outcomes.  Factors that 
contribute to gaps in care during care transitions include poor communication, incomplete 
transfer of information, inadequate education of patients and the absence of a single point person 
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to ensure continuity of care (Naylor & Keating, 2008).  Under the leadership of advanced 
practice registered nurses, such as a DNP prepared nurse practitioner that works in this clinic, 
effective transition among care settings should include collaboration and communication 
between providers, with strategies addressing patient education and medical follow-up during 
transitions (Bradway et al., 2012; Rooney & Arbaje, 2013; Stefanacci, 2011).    
 TCM selected components.  Selected components of TCM (Appendix C) were used for 
implementation of the process improvement protocol in the clinic.  This included: screening, 
assessment, educating patients, coordination and collaboration with the PCP, and assuring 
continuity of care.  Interventions guided by the TCM are usually performed by nurses or 
advanced practice registered nurses [APRNs] (Bradway et al., 2012).  The APRNs perform 
screening to identify and target specific population of adults at risk for poor outcomes 
(Hirschman et al., 2015).  The APRNs conduct comprehensive assessments of adult patients, as 
well as risk factors for poor outcomes during initial meetings with patients (Hirschman et al., 
2015).  Guided by individual patient unique learning styles and preferences, the APRNs utilize 
multiple teaching strategies, such as the use of teach-back for educating patients (Hirschman et 
al., 2015).  The APRNs promote communication and connections between care settings, 
coordinating and facilitating transfer of essential information between care providers 
(Hirschman, 2015).  The APRNs encourage collaboration about plans of care among adult 
patients and members of the care team, and collaborate with physicians involved in care of the 
patient (Hirschman et al., 2015).  The TCM promotes continuity of care to prevent breakdowns 
in care across settings by having the same APRN deliver and coordinate care throughout the 
entire care episode (Hirschman et al., 2015).  The DNP prepared nurse practitioner is an APRN 
with the capability to perform these activities in this particular clinic. 
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The TCM components not chosen for the project included: elders and caregivers, 
symptom management and maintaining relationships.  The “elders and caregivers” component of 
the TCM was not selected as the population of interest in this project is adults of all ages without 
caregivers.  The “symptom management” component of the TCM was not selected as the 
patients with NAFLD may not have symptoms to manage, and NAFLD patient care service is 
not provided at the clinic.  The “maintaining relationships” of the TCM was not selected as the 
DNP prepared nurse practitioner will not be providing health care for patients after treatment of 
their hepatitis C infection.   
 Application of the selected components of the transitional care model.  As part of the 
project protocol, the DNP prepared nurse practitioner at the clinic assumed the role of patient 
care coordinator.  The DNP prepared nurse practitioner implemented the process improvement 
protocol to ensure patients with hepatitis C and hepatitis steatosis are evaluated for and 
diagnosed with comorbid NAFLD and received patient education.  The RN case manager or 
medical assistant screened for hepatic steatosis on radiological imaging in all newly referred 
patients with hepatitis C.  The evaluation for and diagnosis of NAFLD by the DNP prepared 
nurse practitioner occurred during office visits for treatment of the hepatitis C.  The DNP 
prepared nurse practitioner provided patient education about the new NAFLD diagnosis and 
evaluated patient understanding using the teach-back method.  The DNP prepared nurse 
practitioner facilitated the transition of care between specialty care and primary care for 
continued care of NAFLD after completion of hepatitis C treatment.  The DNP prepared nurse 
practitioner communicated with the PCP, to transition patient care for ongoing NAFLD 
management.   
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The process improvement protocol created by the DNP student, was developed with 
consideration given to ease and efficiency of work flow for the clinic team members.  To 
implement this practice improvement, the PDSA Cycle framework was used to plan, implement, 
and evaluate the project.  
Model Guiding Practice Change: Plan-Do-Study-Act (PDSA) Cycle  
 The model guiding the practice change in this scholarly project was the plan-do-study-
act (PDSA).  The PDSA (Appendix D), also known as the Deming Wheel or Deming Cycle, is a 
“systematic series of steps for gaining valuable learning and knowledge for the continual 
improvement of a product or process” (The W. Edwards Deming Institute, 2016, para. 1).    
The PDSA is part of the Institute for Healthcare Improvement Model for Improvement, a 
tool for accelerating quality improvement used in health care (Agency for Healthcare Research 
and Quality [AHRQ], 2013).  A change is planned and implemented, results are studied, and 
action is taken on what is learned (AHRQ, 2013; Litaker et al., 2006; Melnyk & Fineout-
Overholt, 2011).  The overall objective of improving the process or outcome requires problem 
identification, setting goals and planning an intervention, and evaluating outcomes (AHRQ, 
2013; Melnyk & Fineout-Overholt, 2011; Speroff & O’Connor, 2004).  A discussion of use of 
PDSA in this project follows.  
Plan-Do-Study-Act (PDSA) Approach to Project 
Overview           
The four steps of the PDSA Cycle guided the project: (1) plan the intervention; (2) 
implement the intervention; (3) study and analyze the results; and (4) determine what was 
learned.  If the modifications to the plan are needed, then refinement occurs and the plan is 
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implemented again.  These four PDSA Cycle steps guided the practice improvement in the 
following manner. 
Plan-Do-Study-Act (PDSA) Implementation: Planning Phase  
In the plan phase, problems are identified, data are gathered, and the plan to carry out the 
improvement cycle is determined (Murphy, 2013).  A process improvement protocol for patients 
with comorbid hepatitis C and NAFLD was created to improve the quality of patient care 
services using established evidence based guidelines (Chalasani et al., 2012; Sheth & Chopra, 
2014; World Gastroenterology Organization, 2012).  The process improvement protocol was 
developed in collaboration with the clinic DNP prepared nurse practitioner after chart audit, 
observation of the patient care process, and discussion with team members at the clinic. 
Project purpose.  The overall purpose of this DNP scholarly project was to evaluate the 
effectiveness of the practice improvement for patients with hepatitis C and hepatic steatosis.  The 
goal was to improve the process to appropriately screen and diagnose NAFLD in patients with 
hepatitis C, provide patient-centered NAFLD education, and transition care from specialty 
provider to PCP for continued care for NAFLD.   
Project objectives.  This scholarly project had five objectives: 1) increase the number 
of appropriately diagnosed patients with NAFLD by the DNP prepared nurse practitioner during 
treatment of hepatitis C; 2) increase the number of patients with NAFLD who received patient 
education during their final office visit with the DNP prepared nurse practitioner; 3) increase the 
number of discharge letters to PCPs with the NAFLD algorithm for transition of patient care at 
the end of hepatitis C treatment; 4) increase the number of referring PCPs who reported 
awareness of NAFLD diagnosis as evidenced by the PCP questionnaire response; and 5) obtain 
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PCP perceptions of the process improvement protocol as evidenced by their response to a 
questionnaire. 
Project design.  This process improvement project was guided by the TCM, which 
incorporates factors influencing patient care transitions; and the roles of the clinic team 
members.  Opportunities for change vary at each practice, therefore, project design should 
consider existing conditions, practice configuration, and dynamics when a planned change is 
going to occur in clinical practice (Litaker et al., 2006).  The personnel, office configuration, 
existing conditions, practice dynamics and work flow patient care were considered when 
developing the intervention.  The clinic process and patient care routine were considered and 
proposed changes were incorporated into current practice using existing resources.   
The process improvement project involved the development of one protocol with data 
collection during two phases of the protocol.  The first phase of the protocol involved 
identification and diagnosis of NAFLD during treatment of hepatitis C.  The second phase of the 
protocol involved patient education, communication to the PCP with discharge letter along with 
NAFLD algorithm and continuation of care by PCP after treatment of hepatitis C.  Data were 
collected and separated by each phase.  The number of patients who had hepatitis C and hepatic 
steatosis depended on the referral patients receiving treatment at the clinic during the trial period.   
Type of project.  This was a quality improvement project designed to develop and 
evaluate a protocol to address quality care for patients with hepatitis C and NAFLD type hepatic 
steatosis in a community clinic.  Improving patient care services through application of existing 
evidence based practice guidelines will improve patient care (Moran, Burson, & Conrad, 2014).  
Project measurement.  Prior to the process improvement protocol, there was not a 
clinical process or protocol for evaluating and diagnosing NAFLD in patients with hepatitis C 
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and hepatic steatosis at the clinic.  Patients were not receiving NAFLD patient education and 
transitioning to their PCP for continuation of care of NAFLD.  The success of the process 
improvement protocol was determined by a change in current clinical practice.  
There was no patient care services at the clinic for those with hepatitis C and comorbid 
NAFLD.  Thus the plan as presented earlier was developed to: 1) increase in the number 
of appropriately diagnosed patients with NAFLD by the DNP prepared nurse practitioner during 
treatment of hepatitis C; 2) increase in the number of patients with NAFLD who receive patient 
education during their final office visit with the DNP prepared nurse practitioner; 3) increase in 
the number of discharge letters along with the NAFLD algorithm to PCPs for transition of 
patient care at the end of hepatitis C treatment; 4) increase in the number of referring PCPs who 
report awareness of NAFLD diagnosis as evidenced by the return of the PCP questionnaire 
response within seven days of receipt of the questionnaire; and 5) obtain PCP perceptions of the 
process improvement protocol as evidenced by the PCP questionnaire results within seven days 
of receipt of the questionnaire.   
Sources of data.  Data sources included the health records/charts of patients with 
hepatitis C and hepatitis steatosis and the completed PCP questionnaires.  Another source of data 
was the clinic team members’ responses to the question regarding how to improve the process 
improvement protocol. 
Outcome measures.  Data collection occurred during the implementation of the process 
improvement protocol, or “do” phase.  Analyses of the data occurred during the “study” phase.   
A data collection tool, Project Intervention Clinic Process Data Collection Tool 
(Appendix E) was created to collect data on the clinic patient care process to identify and 
diagnose NAFLD.  The first objective of this project was to increase the number of appropriately 
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diagnosed patients with NAFLD by the DNP prepared nurse practitioner during treatment of 
hepatitis C.  The following data were collected using the Project Intervention Clinic Process 
Data Collection Tool.  First, the number of charts with appropriate documentation of hepatic 
steatosis on pre-testing document was identified.  Second, the number of charts with appropriate 
documentation of NAFLD diagnosis on hepatitis C treatment flow sheet were collected.  Third, 
the number of charts with appropriate documentation of calculated NAFLD fibrosis score 
(Angulo et al., 2007) on pre-testing document was identified.  Finally, the number of charts 
appropriately flagged with a green sticker on lab requisition document to send the discharge 
letter along with algorithms to PCP for patients with NAFLD was collected.  Analyses of the 
data occurred to examine documentation of the protocol steps related to the diagnosis of 
NAFLD.  
The second objective of this project was to increase the number of patients diagnosed 
with NAFLD who received patient education during their final office visit with the DNP 
prepared nurse practitioner.  A second data collection tool, Project Intervention Transition Data 
Collection Tool (Appendix F) was created to address the second objective.  Data collected for 
evaluating this objective included: the number of charts with documentation of patients who 
received NAFLD patient education and the patient is able to teach-back information on the 
treatment flow sheet during the final office visit were identified.  Analyses of the data occurred 
to examine documentation of the protocol step related to patients who received NAFLD patient 
education and patients who are able to utilize the teach-back method. 
The third objective for this project was to increase the number of discharge letters along 
with the NAFLD algorithm sent to PCPs for transition of patient care at the end of hepatitis C 
treatment.  Data collected for evaluating this objective included: the number of charts with 
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documentation of the discharge letter along with NAFLD algorithm mailed to the PCP at the end 
of hepatitis C treatment on the patient treatment flow sheet was identified.  Data were recorded 
on the Project Intervention Transition Data Collection Tool.  Analyses of the data occurred to 
examine documentation of the protocol step related to mailed discharge letter along with the 
NAFLD algorithm to the PCP. 
The fourth objective of this project was to increase the number of referring PCPs who 
reported awareness of NAFLD diagnosis as evidenced by the PCP questionnaire response within 
seven days of receipt of questionnaire.  A third data collection tool, Primary Care Provider 
(PCP) Questionnaire (Appendix G) was created to collect data to address the fourth objective.  
Data collected for evaluating this objective included: the number of PCPs who reported receipt 
of the discharge letter, and the number of PCPs who reported awareness of NAFLD diagnosis 
with the addition of diagnosis to the patient’s health record.  The questionnaire data were 
analyzed for the PCPs “yes or no” response to receipt of the discharge letter and addition of 
NAFLD diagnosis to the patient health record.  
The fifth objective of this project was to evaluate the PCP perceptions of the protocol 
process as evidenced by the PCP questionnaire response within seven days of receipt of the 
questionnaire.  Data were collected using the Primary Care Provider Questionnaire: the number 
of PCPs who reported receipt of the NAFLD algorithm; and the number of PCPs who evaluated 
the NAFLD algorithm for management of NAFLD.  In addition, comments from the PCPs 
regarding the transition of care from specialty provider to PCPs for continuation of NAFLD 
treatment were collected.  The questionnaire data from the PCPs’ response “yes or no” to receipt 
and usefulness of the algorithm for management of NAFLD were analyzed, and a summary of 
comments for themes regarding the transition of care was conducted.  PCPs who did not return 
IDENTIFICATION OF NONALCOHOLIC FATTY LIVER DISEASE             30 
 
the questionnaires within seven business days received a phone call to encourage return of the 
completed questionnaire and this data were included.  The DNP student also interviewed the 
clinic team members during the implementation phase of the protocol.    
The DNP student interviewed the clinic DNP prepared nurse practitioner and the RN case 
manager to evaluate the process improvement protocol, and inquired how the process 
improvement protocol could be improved.  The clinic team members’ recommendations for 
patient care document changes were made the same day as recommended.  The clinic team 
members’ recommendations for changes and additions in steps of the protocol were recorded and 
incorporated into the revised protocol.   
Plan-Do-Study-Act (PDSA) Implementation: Do Phase   
Prior to implementation of the project, the proposed intervention was formally approved 
by the project team; and the Institutional Review Boards (IRBs) of both the organization and the 
university.  A timeline for the project was created using the PDSA framework.  During the “do” 
phase, the plan is implemented, problems are documented, and data analysis is initiated 
(Murphy, 2013).  The RN case manager and DNP prepared nurse practitioner used the process 
improvement protocol at the clinic during the implementation phase.   
Steps to implement project.  The process improvement protocol intervention consisted 
 of the following steps.  First, the RN case manager and medical assistant identified patient 
referrals with hepatic steatosis during chart preparation and made written notations on the chart 
of imaging results.  Second, the DNP prepared nurse practitioner evaluated and diagnosed 
NAFLD during the treatment for hepatitis C.  Third, the DNP prepared nurse practitioner 
provided NAFLD patient education and used teach-back during the final scheduled appointment 
at the clinic.  Fourth, the discharge letter along with NAFLD algorithm was sent by the DNP 
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prepared nurse practitioner to the PCP at the end treatment of hepatitis C infection.  Fifth, the 
DNP student contacted the primary care office clinical staff and faxed the PCP questionnaire to 
the referring provider for completion two weeks after patient completed hepatitis C treatment.  
Finally, the DNP student contacted the PCP office staff to check on questionnaire status, if not 
returned to the clinic in seven days.  Data from questionnaires returned after seven days were 
included.    
The DNP student collected data during the implementation of the protocol intervention at 
the clinic.  The clinic team members were interviewed during the implementation phase for 
comments about the process improvement protocol intervention.   
Training clinic team members.  The DNP student met with the clinic team members on 
July 8, 2016 the week before implementation. The meeting was conducted to review the 
protocol, roles, documents to use during implementation; and to answer questions.   
Documents for the evidence-based project.  The DNP student generated the tools and 
documents used for this project.  The process improvement protocol, Patient Referral to Clinic 
with Hepatic Steatosis (Appendix H) outlined a step-by-step protocol process and the Diagram 
of Protocol for Patient Referral to Clinic with Hepatic Steatosis (Appendix I) is a visual 
representation of the protocol.   
The DNP student developed the DNP prepared nurse practitioner’s Discharge Letter from 
Specialty to Primary Care Provider (Appendix J) along with the Hepatic Steatosis Noted on 
Radiological Imaging Algorithm (Appendix K) and NAFLD Algorithm (Appendix L).  The 
documents were developed to send to PCPs when patients completed hepatitis C treatment and 
needed follow up for NAFLD.  The documents were mailed through the US Postal Service to the 
PCP, in the absence of an electronic health record.   
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Patients received NAFLD education using the DNP student generated Nonalcoholic Fatty 
Liver Disease (NAFLD) Patient Education Handout (Appendix M ) during their final office visit 
at the end of hepatitis C treatment.  The patients were expected to teach-back NAFLD patient 
information and follow up needed with his or her PCP, to ensure comprehension of instructions.  
The DNP prepared nurse practitioner asked patients to teach-back key points for NAFLD 
management and follow up with their PCP as noted on his or her patient NAFLD education 
handout and included in patient education session with provider.  
Recruitment strategies.  There was no recruitment of patients, as patients with hepatitis 
C infection are referred to the clinic for treatment.  A proportion of the patients with hepatitis C 
had hepatic steatosis reported on radiological imaging.  After the project proposal was approved 
and IRB determination, a patient chart review was performed at the clinic by the DNP student 
identifying patients receiving treatment for hepatitis C with hepatic steatosis reported on 
radiological imaging.   
Timeline for project. 
January – June 2016 
 
 Organization assessment.  
 Design of protocol, protocol diagram, algorithms, patient education handout, 
discharge letter and PCP questionnaire, and data collection tools. 
July – August 
 2016 
 
 Meeting with clinic team members to review project intervention;  
 RN case manager, medical assistant and DNP prepared nurse practitioner began use 
of protocol in patient care process; 
 DNP prepared nurse practitioner reviews patient’s health history, assessed for alcohol 
abuse, and reviews laboratory results to rule out differentials for diagnosis of 
NAFLD; 
 NAFLD patient education from the DNP prepared nurse practitioner during their 
final office visit for treatment of hepatitis C; 
 The discharge letter along with NAFLD algorithm mailed by the DNP prepared nurse 
practitioner to the PCP after their patient has completed hepatitis C treatment; 
 The DNP student faxed questionnaire to referring PCP two weeks after the discharge 
letter with algorithms is mailed to the PCP;   
 The DNP student contacted the clinical staff at the PCP’s office if the questionnaire 
was not returned in seven days; and  
 Data collection occurred during implementation of protocol. 
September 2016 
 
 Analysis of data from collection tools for the clinical process – increased percentage 
in diagnosis of NAFLD, patient education and transition of care, and continuity of 
care for patients with hepatitis C and comorbid hepatic steatosis. 
 Project Intervention Clinic Process Data Collection Tool 
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 Project Intervention Transition Data Collection Tool 
 Primary Care Provider (PCP) Questionnaire  
 Updated the protocol intervention with solutions for the identified problems in 
preparation for the next PDSA Cycle.  
 Decision about sustainability of intervention after first PDSA completed.         
 Meeting with clinic team members and nursing director to present results of the 
project process improvement protocol. 
  
Budget.  There was not a budget for the project.  There were minimal costs, as the project 
incorporated changes to clinical practice without an increase in personnel.  However, it did have 
an additional cost of $0.07 for a color copy of the NAFLD algorithm that accompanied the 
discharge letter.  The DNP prepared nurse practitioner and RN case manager incorporated the 
assessment for and education of patients with NAFLD into the patient care routine.   
Project implementation required additional time by the DNP prepared nurse practitioner 
to evaluate patients whose radiological imaging reports hepatic steatosis.  In addition, the DNP 
prepared nurse practitioner required additional time to provide NAFLD education, and send the 
discharge letter with the NAFLD algorithm to the PCP.  The patient’s last appointment encounter 
with the DNP prepared nurse practitioner had two diagnoses, hepatitis C and NAFLD; and was 
10 minutes longer.  Approximately 50 percent of the visit devoted to educating and counseling 
patients.  The increased time for the last appointment resulted in a potential increase in revenue 
as a Level 4, established visit at $184.00; instead of Level 3, established visit at $152.00.  The 
DNP student created the project documents (i.e., protocol, algorithms, discharge letter, patient 
education material, and PCP letter with questionnaire) used in the project at no cost to the 
organization.  All documents were left with the clinic DNP prepared nurse practitioner for 
continued use.   
Human subject protection.  The human subject considerations are minimal because this 
is a scholarly quality improvement project establishing patient care process at the clinic.  The 
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DNP student completed and submitted the DNP Application for Review of Determination to the 
Grand Valley State University Human Research Review Committee for review.  Likewise, the 
DNP student completed and submitted an application to the organization’s Health Human 
Research and Review Board.  The project was deemed to be a clinical quality improvement 
initiative and not research by both review boards (Appendix N).   After approval was obtained 
from both review boards the project was implemented. 
The data collection tools and questionnaire were de-identified to protect patient 
confidentiality using a numeric value instead of the patient name.  The numeric de-identifier 
code key and data collection tools were stored in the DNP prepared nurse practitioner designated 
locked desk drawer in a locked office at the clinic, to protect patient confidentiality.   
There was a private fax machine located within the clinic office to fax the PCP 
Questionnaire Letter (Appendix O) from the DNP student to the PCP using a clinic fax cover 
sheet (Appendix P) for transmission.  The completed questionnaire from the PCP was faxed to 
the DNP prepared nurse practitioner using the clinic fax cover sheet (Appendix Q) to the clinic 
fax machine.  The RN case manager at the clinic gave received faxed questionnaire to the DNP 
prepared nurse practitioner.  The DNP student checked with the DNP prepared nurse practitioner 
at the clinic weekly for the completed PCP questionnaires.   
Plan-Do-Study-Act (PDSA) Implementation: Study Phase   
Overview.  In the study phase, data analysis was completed and included a determination 
of whether project aims were met (Murphy, 2013).  Data collected during the implementation or 
“do” phase was analyzed.  Data from collection tools were analyzed to evaluate the effectiveness 
of the practice improvement for patients with hepatitis C and hepatic steatosis.   
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Data analysis.  Descriptive statistics were used to summarize the quantitative data.  A 
qualitative thematic analysis was used to analyze one of the responses from the PCPs.  An 
increase in the percentage of patients with hepatitis C who were diagnosed, received patient-
centered education and transitioned to their PCP for continued care of NAFLD would support the 
effectiveness of the protocol.   
In a clinical setting, approximately 30 to 70 percent of patients with hepatitis C have 
hepatic steatosis (Blonsky & Harrison, 2008; Patel & Harrison, 2012; Rafiq & Younossi, 2008).  
Seven patients or 30 percent of the average number of monthly patient referrals to the clinic were 
required for evaluation of the process improvement protocol intervention, but this number was 
not possible within the eight week trial period.  The number of patients for the PDSA cycle was 
determined by the patients with hepatitis C and hepatic steatosis referred to the clinic and 
received treatment during the trial period.  It would have been ideal to receive all of the 
questionnaires from PCPs to analyze.  However, the number of questionnaire responses for 
evaluation was dependent upon on the number of questionnaires returned to the clinic during the 
trial period. 
Plan-Do-Study-Act (PDSA) Implementation: Act Phase 
During the final phase, “act,” decisions are made about sustainability of the process 
improvement protocol, and if necessary, another round of PDSA (Murphy, 2013).  Clinic team 
members used the protocol to improve patient care process for patients with hepatitis C and 
hepatic steatosis.  The patients with hepatitis C and hepatic steatosis were diagnosed with 
NAFLD, received patient-centered education, and transitioned to their PCP for continued 
management of NAFLD after completion of hepatitis C treatment at the clinic.  The clinic team 
members plan to continue the process improvement protocol with recommended revisions.  A 
IDENTIFICATION OF NONALCOHOLIC FATTY LIVER DISEASE             36 
 
second PDSA cycle is recommended with use of revised patient care process.  A discussion of 
the project outcomes and implications for practice follows.  
Project Outcomes 
Review of the process improvement project involved the development of one protocol 
with data collection during two phases of the protocol.  The first phase of the protocol involved 
identification and diagnosis of NAFLD during treatment of hepatitis C.  The second phase of the 
protocol involved patient education, communication to the PCP with discharge letter along with 
NAFLD algorithm and continuation of care by PCP after treatment of hepatitis C.  Data were 
collected and separated by each phase.  During the PDSA cycle, only six patients receiving 
hepatitis C treatment with hepatitis steatosis noted on radiological imaging at the clinic were 
included.  During the trial period, there was four new patient referrals to the clinic for hepatitis C 
with hepatic steatosis noted on radiological imaging pending treatment, but they did not begin 
treatment for hepatitis C during the trial period to include in the PDSA cycle. 
The trial period for the process improvement protocol occurred from July 11, 2016 to 
September 12, 2016 and included six patients receiving treatment for hepatitis C at the clinic 
(Table 1).  The six patients included four male (66.7%) and two female (33.3%) with age range 
from 40 to 69 years.  Three of the six patients reported their race as White (50%) and three as 
African Americans (50%).  Four of the six patients had hepatitis C genotype 1A (66.7%) and two 
patients had hepatitis C genotype 1B (33.3%).   
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Table 1 
Participant Information 
Characteristic     n=6  
 
Sex 
 
Male 3 (50%) 
 
Female 3 (50%) 
 
Race 
 
African American 3 (50%) 
 
White 3 (50%) 
 
Hepatitis C Genotype 
 
1A 4 (66.7%) 
 
1B 2 (33.3%) 
 
Project Objectives 
To review, the scholarly project had five objectives: (1) increase the number 
of appropriately diagnosed patients with NAFLD by the DNP prepared nurse practitioner during 
treatment of hepatitis C; (2) increase the number of patients with NAFLD who received patient 
education during their final office visit with the DNP prepared nurse practitioner; (3) increase the 
number of discharge letters mailed to PCPs with the NAFLD algorithm for transition of patient 
care at the end of hepatitis C treatment; (4) increase the number of referring PCPs who reported 
awareness of NAFLD diagnosis as evidenced by the PCP questionnaire response; and (5) obtain 
PCP perceptions of the protocol as evidenced by their response to a questionnaire. 
 Objective one.  The objective to increase the number of appropriately diagnosed patients 
with NAFLD by the DNP prepared nurse practitioner during treatment of hepatitis C was 
achieved with all six patients or 100 percent of the patients with hepatitis C and hepatic steatosis 
diagnosed with NAFLD (Table 2).  Data collected for hepatic steatosis noted on the clinic 
pretesting document occurred four out of six opportunities (66.7%).  Data collected for NAFLD 
diagnosis noted on the clinic hepatitis C treatment flow sheet occurred six out of six 
opportunities (100%).  Data collected for calculated NAFLD fibrosis score noted on the clinic 
pretesting document occurred three out of six opportunities (50%).  Data collected for green 
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sticker on the lab requisition document to send PCP letter and NAFLD algorithm occurred six 
out of six opportunities (100%).  Even though these six patients were not screened for and 
diagnosed with NAFLD at the first office visit, the DNP prepared nurse practitioner’s knowledge 
of the process improvement protocol and NAFLD enabled her to screen for and diagnosis 
NAFLD at later patient encounters during treatment of hepatitis C.  The DNP prepared nurse 
practitioner included the NAFLD diagnosis in the final patient encounter dictation note sent to 
the PCP. 
Table 2 
Phase 1: Objective 1 Assessment and Diagnosis of NAFLD  
Protocol Step Yes No                       n=6 
 
Hepatic steatosis noted on 
pretesting document 
 
4 (66.7%) 
 
2 (33.3%) 
 
NAFLD diagnosis noted on 
treatment flow sheet 
 
6 (100%) 
 
 
 
Fibrosis score noted on 
pretesting document 
 
3 (50%) 
 
3 (50%) 
 
Green sticker placed on lab 
requisition document 
 
6 (100%) 
 
 
 
 Objective two.  The objective to increase the number of patients with NAFLD who 
received patient education during their final office visit with the DNP prepared nurse 
practitioner.  Data collected for NAFLD patient education with teach-back at final office visit 
recorded on the clinic treatment flow sheet occurred two out of six opportunities (33.3%).  The 
DNP prepared nurse practitioner reported all of the six patients or 100 percent of patients with 
newly diagnosed NAFLD received patient education with the teach-back method.  Patient chart 
review of the dictation note from the final patient encounter with the DNP prepared nurse 
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practitioner noted NAFLD patient education for all six patients (100%), but only three of the six 
dictations (50%) noted the use of teach-back method.  The DNP prepared nurse practitioner 
reported she forgot to dictate the teach-back method with the NAFLD education in three of the 
patient encounters due to new process.  She also reported duplication of putting information both 
in patient encounter dictation note and on clinic treatment flow sheet. 
Objective three.  The objective to increase the number of discharge letters mailed to 
PCPs with the NAFLD algorithm for transition of patient care at the end of hepatitis C treatment.  
Three out of six opportunities (50%) occurred with recording completion of mailed letter with 
NAFLD algorithm mailed to PCP noted on the clinic treatment flow sheet.  The DNP prepared 
nurse practitioner reported she forgot to record information on the clinic treatment flow sheet for 
some of the patients.  She reported all six patients’ PCP were mailed a discharge letter with 
NAFLD algorithm and noted duplication of recording information on clinic treatment flow sheet 
when a copy of letter was in the patient health record. 
 Objective four.  The objective to increase the number of referring PCPs who report 
awareness of NAFLD diagnosis as evidenced by the PCP questionnaire response.  Response 
rates or return of PCP questionnaires was low with a return rate of four (66.7%) questionnaires.  
If the PCP did not return the questionnaire, the DNP student called the PCP’s office and spoke 
with the medical assistance to encourage the PCP to complete the questionnaire and fax back to 
the clinic.  The four (66.7%) returned PCP questionnaires were affirmative to the following 
questions indicating awareness of NAFLD diagnosis and usefulness of NAFLD algorithm.  Two 
(33.3%) PCP questionnaires were not returned. 
1. Did you receive the patient’s discharge letter from the clinic provider noting diagnosis of 
nonalcoholic fatty liver disease (NAFLD)?                                                                       
Yes 100% of returned questionnaire      No _________         
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2. Was the diagnosis of NAFLD added to the patient’s medical history or problem list?   
Yes 100% of returned questionnaires   No ________      
Objective five.  The objective to obtain the PCP’s perceptions of the process improvement 
protocol as evidenced by their response to a questionnaire.  Again the PCP response rate with 
return of the questionnaire was low with four (66.7%) returned questionnaires and two (33.3%) 
questionnaires not returned.  PCPs who responded to questions three and four were affirmative 
indicating receipt and usefulness of NAFLD algorithm.  One of the PCPs reported he did not 
receive the NAFLD algorithm.  A NAFLD algorithm was faxed to this PCP with a request to 
provide a response to question four and the PCP responded. 
3. Did you receive the NAFLD algorithm sent with the discharge letter from the Mercy Health 
Hepatitis C Clinic provider?                                                                                                         
Yes 75% of returned questionnaires    No 25% of returned questionnaires      
4. Was the algorithm beneficial for the treatment/management of NAFLD?                  
            Yes 100% of returned questionnaires    No ________     
5. Are there any suggestions for improvement of the process for transition of care from 
specialty care to primary care for the continuation of treatment for NAFLD?  
 
There was no suggestions for improvement of the process for transition of care from the 
clinic provider to the PCP in response to question five.  Two questionnaires included a comment 
of “no” by the PCP and two questionnaires had no comments or left blank by the PCP.  A 
telephone conversation with the nurse of one of the PCPs, informed the DNP student that the 
PCP had the questionnaire on her desk but was too busy to complete it due to her work load.                                                                   
Interviews with clinic team members.  The DNP student led interviews with the DNP 
prepared nurse practitioner and RN case manager occurred weekly throughout the project 
implementation “do” phase.  The clinic team members reported ease of use of the protocol and 
made the following recommendations during the “do” phase of the project and were changed the 
same day of recommendation: 1) addition of recommended weight loss of 10 percent to the 
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NAFLD patient education document; 2) update of new fax number on clinic fax cover sheet; and 
3) revision of letter to the PCP regarding follow up lab for patient in three months to determine 
hepatitis C viral cure to more accurately reflect the significance of lab result.   
The following recommendations made by the clinic team members during the “do” phase 
of the project were recorded and included in the revised protocol: 1) discontinuation of NAFLD 
calculated fibrosis score and replace it with the Fibroscan 502 Touch (Echosens) hepatic 
steatosis and fibrosis scores; 2) stop recording patient education on clinic treatment flow sheet 
and continue including in patient encounter dictation note to the PCP; 3) send the discharge letter 
to PCP with NAFLD algorithm when end of treatment lab results are obtained instead of date of 
lab draw; 4) continue to include a copy of the discharge letter in patient’s chart and stop 
recording information on the clinic treatment flow sheet; and 5) include NAFLD patient 
education for appropriate patients during the consultation visit as well as the last office visit with 
the DNP prepared nurse practitioner. 
 Summary. There was a change in clinical practice at the clinic resulting in an improved 
patient care process for patients with hepatitis C and hepatic steatosis.  The following are results 
of the process improvement protocol for the clinic site, PCP clinicians and patients.   
Site.  The clinic team members reported ease of use of the process improvement protocol.  
The clinic team members incorporated and used the process improvement protocol in clinical 
practice.  The clinic team members provided recommendations for improvement of the process 
improvement protocol resulting in the creation of a revised protocol to use for a second PDSA 
cycle. 
Clinicians.  Primary care providers’ responses to the questionnaire were positive for 
NAFLD awareness and NAFLD diagnosis added in patient health care record.  The PCP 
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responses were positive for the usefulness of the NAFLD algorithm.  There was only two 
comments of “no” from the PCPs regarding suggestions for improvement of transition of care 
process from specialty to primary care provider. 
Patients.  Patients were diagnosed with NAFLD, received NAFLD education with teach-
back method for comprehension of information and the need for follow up with PCP.  Patient 
were transitioned to their primary care provider for continued care of NAFLD after hepatitis C 
treatment.    
Implications for Practice 
Successes                                                                                                                         
 Successes encountered in the project included: 1) the clinic team members supported the 
use of the process improvement protocol; 2) the clinic team members provided feedback on the 
process improvement protocol to improve the process; 3) all of the clinic patients with hepatitis 
C who had comorbid hepatic steatosis were screened and diagnosed with NAFLD; 4) the DNP 
prepared nurse practitioner provided patient-centered NAFLD education using the teach-back 
method; 5) the clinic patients transitioned care from specialty provider to their PCP for continued 
care for NAFLD; 6) a change in clinical practice occurred; and 7) a revised process improvement 
protocol (Appendix R) for patients with hepatitis C and hepatic steatosis was developed and 
provided to the clinic team members to use in a second PDSA cycle.   
Barriers 
 Barriers encountered in the project included: 1) a delay in implementation of the protocol 
resulted in a smaller number of patients for the project trial period; 2) a delay in new referral 
patients to the clinic starting hepatitis C treatment due to pending patient lab results and/or prior 
authorization for medication resulted in a small sample size to evaluate the protocol; 3) the 
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medical assistant was absent from the clinic on leave during implementation of the protocol and 
not available to provide feedback on the protocol; 4) the RN case manager was absent from the 
clinic for two weeks on vacation during the implementation phase and not available for 
processing new referral patients’ for treatment of hepatitis C and prepping charts; 5) incomplete 
documentation of protocol steps by the DNP prepared nurse practitioner in the health record for 
several of the patients; and 6) a low return rate (66.7%) of completed questionnaires by the 
PCPs. 
Sustainability Plan 
The ease of use of the process improvement protocol reported by the clinic team 
members helped to sustain use of the intervention at the clinic during the trial period.  The clinic 
team members plan to continue the change in clinical practice with the revised process 
improvement protocol for new referral patients with hepatitis C and hepatic steatosis.  The 
questionnaire sent to the referring PCPs was discontinued at the end of the trial period when the 
DNP student departed from the clinic.  The clinic DNP prepared nurse practitioner did not want 
to continue the questionnaire to the PCPs, as it was a method to collect data during the quality 
improvement PDSA cycle with favorable responses from PCPs who returned the questionnaire. 
The clinic does not have an electronic health care record and uses paper records.  In the 
future, when an electronic health record is available at the clinic, the process improvement 
protocol could become part of the electronic health record to document diagnosis of NAFLD and 
document NAFLD patient education.  The electronic health record could also be used to 
document transition of patient care to referring PCP via electronic discharge letter with NAFLD 
information for continuation of care.  The process improvement protocol may require a PDSA 
cycle to ensure improvement continues after a conversion to an electronic health record.   
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There is potential to generate revenue for reimbursement of services at the clinic as a 
result of using the process improvement protocol in the care of patients with comorbid hepatitis 
C and NAFLD.  The increased time for the last patient appointment with the provider for 
education resulted in an increase in revenue as a Level 4, established visit at $184.00; instead of 
Level 3, established visit at $152.00.  However, there was an additional cost of $0.07 for a color 
copy of the NAFLD algorithm that accompanied the discharge letter to the PCP.  The additional 
revenue for reimbursement of services during the implementation phase of the protocol for the 
six patients was $31.93 per patient for a total of $191.58 (Table 3).  Future potential revenue for 
the clinic includes the Fibroscan fee of $230.00 per patient referred to the clinic for hepatitis C 
treatment to evaluate patients for hepatic fibrosis and steatosis.   
Table 3 
Increased Clinic Revenue for Reimbursement of Services 
Total Number  
of Patients 
Level 4 Visit 
Fee Total 
Minus Level 3 
Visit Fee Total 
Minus Total 
Print Cost of 
Algorithm 
Net Increase in 
Clinic Revenue 
 
6 
 
$1,104.00 
 
$912.00 
 
$0.42 
 
$191.58 
   
Stakeholder support.  Key stakeholders in this project included the DNP prepared nurse 
practitioner, the collaborating physician, nursing director, the RN case manager, and the medical 
assistant.  The clinic DNP prepared nurse practitioner had requested assistance to provide care 
for patients with hepatitis C with undiagnosed NAFLD.  The clinic team members willingly 
incorporated the process improvement protocol into their care for patients to improve patient 
care.  The process improvement protocol gave the clinic team members the needed evidence-
based intervention to improve patient care services to address an identified gap in care.   
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The transition of care from specialty practice to primary care for continued care was 
supported by clinic team members and the referring PCPs.  The PCP’s acknowledgement of 
NAFLD diagnosis and usefulness of the NAFLD algorithm regarding the transition process of 
patient care helped sustain the process improvement protocol by the clinic team members. 
Relationship to Healthcare Trends 
Early identification and treatment of NAFLD.  Hepatitis C is an example of one 
chronic disease associated with NAFLD.  Undiagnosed NAFLD in susceptible patients with 
hepatitis C may lead to disease progression of NASH, cirrhosis, liver failure and possibly HCC 
requiring liver transplantation (Chalasani et al., 2012; Stein, Dong, & Loomba, 2009; Wong et 
al., 2014).   
Early identification of NAFLD and treatment could prevent the development of 
nonalcoholic steatohepatitis, cirrhosis, liver failure and possibly hepatocellular carcinoma 
(Loomba & Sanyal, 2013).  Health care providers are key in early identification of NAFLD for 
treatment not only in patients with hepatitis C, but other patients with risk factors for NAFLD, 
such as obesity and type 2 diabetes.  The DNP student’s process improvement protocol provided 
patient care services for identification of NAFLD by the DNP prepared nurse practitioner during 
treatment of hepatitis C.  The DNP student’s process improvement protocol improved the 
transition of patient care to the PCP for continuation of treatment of NAFLD preventing disease 
progression and early death.   
Transition of care.  Patients with complex or comorbid health conditions frequently 
require care from multiple providers and are particularly vulnerable to poorly executed 
transitions from one setting to another (Jeffs, Lyons, Merkley & Bell, 2013).  Van Cleave et al. 
(2013) reported individuals with comorbidities experiencing care transitions is a challenge to the 
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health care system.  Poorly executed care transitions can result in negative patient outcomes such 
as delays in treatment and increased healthcare spending due to progression of chronic disease 
(Jeffs, et al., 2013).  Strategies addressing patient education, appropriate medical follow-up, and 
communication between providers improved the quality of care during transitions (Rooney & 
Arbaje, 2013).   
The DNP student process improvement protocol, Identification of Nonalcoholic Fatty 
Liver Disease in Patients with Hepatitis C: Using Evidence Based Guidelines to Improve 
Diagnosis and Transition of Care from Specialty Care Provider to Primary Care Provider, 
addresses quality of care during transitions using the TCM.  The TCM guided the development 
of the protocol, utilizing screening, assessment, patient education, coordination, collaboration 
and continuity of care by the DNP prepared nurse practitioner at the clinic.  The use of the TCM 
by nurse practitioners may be benefit other patients with comorbid diseases and multiple health 
care providers during transition among care settings in the community. 
Limitations 
 
There was a small number of participants during the process improvement protocol trial 
period.  During the trial period, six patients with hepatitis C and hepatic steatosis received 
treatment at the clinic available for evaluation and diagnosis of NAFLD, patient education and 
transition to the PCP for continued management of NAFLD.  Four new referral patients for 
treatment of hepatitis C with hepatic steatosis on radiological imaging were excluded because 
that did not start treatment during the process improvement protocol trial period.  There was no 
follow up with the six patients to determine if the patient scheduled an appointment with their 
PCP at the end of hepatitis C treatment for continued management of NAFLD.  An additional 
limitation was the number of PCPs who provided feedback on the transition process from the 
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clinic provider to the PCP.  A second PDSA cycle is recommended using the revised process 
improvement protocol at the clinic for patients with hepatitis C and hepatic steatosis.   
Essentials of Doctoral Education for Advanced Nursing Practice  
The American Association of Colleges of Nursing (AACN) document, The Essentials of 
Doctoral Education for Advanced Nursing Practice (2006) reports the Doctor of Nursing 
Practice (DNP) is a practice-focused doctorate that should prepare clinicians for leadership in 
evidence-based practice.  The DNP degree prepares clinicians to generate and translate evidence 
produced through research into practice to improve health care quality, patient outcomes, and 
organizational or health policy (Melnyk, 2013).  The DNP Essentials (2006) document provides 
content areas necessary for DNP curricula and the outcome competencies for graduates of DNP 
programs.  The AANC (2006) DNP Essentials curriculum standards include: 1) scientific 
underpinnings for practice; 2) organizational and systems for quality improvement and systems 
thinking; 3) clinical scholarship and analytical methods for evidence-based practice; 4) 
information systems and technology and patient care technology for the improvement and 
transformation of health care; 5) healthcare policy for advocacy in health care; 6) inter-
professional collaboration for improving patient and population health outcomes; 7) clinical 
prevention and population health for improving the nation’s health; and 8) advanced nursing 
practice.  The DNP student is able to translate research into practice, evaluate and change 
practice (Brown & Crabtree, 2013).   
As a DNP student, knowledge acquisition and competencies were obtained through the 
DNP curricula and the DNP project or practice change in the following ways: 1) performed an 
extensive literature review with synthesis on the project topic and utilized three theoretical 
frameworks in assessment, planning, implementing and evaluating the project; 2) enacted the 
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organization leaderships role through applied knowledge and skills in assessment of the 
organization and the community where the clinic is located to promote a quality improvement 
patient care process; 3) applied evidence appraisal and translation of evidence for best practice to 
change clinical practice at the clinic; 4) utilized change theory to plan and implement a quality 
improvement process with evaluation at the clinic; 5) advocated for care of patients with chronic 
liver disease when a gap in care was discovered at the clinic to improve patient quality of care; 6) 
communicated and collaborated with inter-professional and intra-professional team members at 
the clinic and in the community to improve patient health outcomes; and 7) portrayed the 
advanced practice nurse leadership role in project conception, assessment, development, 
implementation and evaluation of the process improvement at the clinic. 
Brown and Crabtree (2013) report the DNP project requires students to use their 
knowledge to solve practice problems and meet the needs of patient populations to improve 
health care quality and patient outcomes.  This DNP student’s process improvement protocol for 
the clinic improved the patient care process for patients with hepatitis C and hepatic steatosis.   
Patients with hepatitis C and hepatic steatosis benefited from early identification and diagnosis 
of NAFLD, patient-centered NAFLD education, and transition from specialty to primary care for 
NAFLD management after treatment of hepatitis C.   
Dissemination Plan 
Findings from the project will be disseminated to share information that may be useful in 
clinical practice for patients with hepatitis C and other chronic diseases associated with NAFLD.  
Dissemination of the project will begin through the DNP student’s presentation of the project 
results to the clinic team members and nursing director on September 19, 2016.  The formal 
defense of the project on September 26, 2016 provides another venue for dissemination.  The 
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DNP student presented on the topics NAFLD and NASH with the clinic DNP prepared nurse 
practitioner, liver disease presentation at the Michigan Society of Gastroenterology Nursing and 
Associates Conference on September 24, 2016.  Future dissemination included submission of a 
manuscript for publication. 
Conclusion 
The development of a process improvement protocol filled a gap in care of patients with 
hepatitis C and hepatic steatosis at the clinic.  The recognition of risk factors and assessment for 
NAFLD in patients with hepatitis C and hepatic steatosis will help promote early diagnosis and 
management of NAFLD to prevent progression of liver disease.  NAFLD information from the 
DNP prepared nurse practitioner to the PCP assisted with the transition of care for patients with 
NAFLD for ongoing management and monitoring for disease progression by their PCP.  Patient 
education enabled the patient’s participation in self-care and follow up with their PCP. 
This DNP student’s quality improvement project may be useful for clinical practice in 
other primary and specialty practice settings, to diagnose and manage patients with NAFLD, and 
facilitate patient care transitions.  Health care providers are key in early identification of NAFLD 
for treatment not only in patients with hepatitis C, but other patients with risk factors for 
NAFLD, such as obesity and type 2 diabetes.  Early identification of NAFLD and treatment 
could prevent the development of nonalcoholic steatohepatitis, cirrhosis, liver failure and 
possibly hepatocellular carcinoma (Loomba & Sanyal, 2013).   
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Appendix A  
 
Canadian International Developmental Agency - Universalia/IDRC Framework 
 
 
 
Source: Retrieved from 
http://documents.reflectlearn.org/Offline%20Docs%20for%20Your%20Introductory%20Guide%
20to%20OA/OA%20Guide-E.pdf  
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Appendix B 
 
Transitional Care Model (TCM)  
 
 
 
 
 
 
Source: Reproduced with permission from the Transitional Care Model 
http://www.transitionalcare.info   
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Appendix C 
 
Selected Components of the Transitional Care Model (TCM)  
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Appendix D 
 
 Plan-Do-Study-Act (PDSA) Cycle 
 
 
 
 
 
Source: PDSA Cycle reprinted with permission courtesy of The W. Edwards Deming Institute®. 
https://www.deming.org/theman/theories/pdsacycle  
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Appendix E 
 
Project Intervention Clinic Process Data Collection Tool 
De-identifier 
 
Hepatic steatosis 
noted on the clinic 
pretesting document 
Yes or No  
NAFLD diagnosis noted on 
the clinic hepatitis C 
treatment flow sheet               
Yes or No 
NAFLD fibrosis score noted 
on the clinic pretesting 
document 
Yes or No 
NAFLD green sticker on the 
clinic lab requisition 
document to remind nurse 
practitioner to send letter and 
NAFLD algorithm  
Yes or No 
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Appendix F 
 
Project Intervention Transition Data Collection Tool 
De-identifier 
 
NAFLD patient 
education with teach-
back final office visit 
noted on the clinic 
treatment flow sheet  
Yes or No                      
Discharge letter with 
NAFLD algorithm 
mailed to PCP two 
weeks after final 
office visit noted on 
the clinic treatment 
flow sheet  
Yes or No    
Date: 
Fax questionnaire to 
the PCP two weeks 
after the letter with 
NAFLD algorithm 
mailed 
Date:   
 
Questionnaire 
returned from 
PCP 
Yes or No 
Date: 
Telephone call to 
the PCP’s office if 
questionnaire is not 
returned in seven 
days. 
Date: 
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Appendix G 
 
Primary Care Provider (PCP) Questionnaire  
 
Primary Care Provider: _________________________________   De-identifier: ___________ 
Phone Number: ___________________________   Fax Number: _________________________ 
1. Did you receive the patient’s discharge letter from the Hepatitis C Clinic provider noting 
diagnosis of nonalcoholic fatty liver disease (NAFLD)?   
Yes _______    No _________ 
2. Was the diagnosis of NAFLD added to the patient’s medical history or problem list?   
Yes _______    No ________ 
3. Did you receive the NAFLD algorithm sent with the discharge letter from the Hepatitis C 
Clinic provider?  
Yes ________    No _________ 
4. Was the algorithm beneficial for the treatment/management of NAFLD?     
Yes ______   No ________     
5. Are there any suggestions for improvement of the process for transition of care from 
specialty care to primary care for the continuation of treatment for NAFLD?  
 
 
 
 
 
Thank you for your time and assistance with completing the questionnaire. 
Please use the accompanying Hepatitis C Clinic cover sheet with the questionnaire and fax back 
to the Hepatitis C Clinic provider.  
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Appendix H 
 
Protocol Process for a Patient Referral to Hepatitis C Clinic with Hepatic Steatosis  
 
1. Referral received from primary care provider (PCP) to the clinic for treatment hepatitis C by 
registered nurse (RN) case manager or medical assistant. 
 
2. Review of referral patient’s required health history, labs and ultrasound of right upper 
quadrant (RUQ) in preparation of hepatitis C treatment by RN case manager or medical 
assistant and patient health record is prepared for first clinic visit. 
 
3. Radiological imaging results negative for cirrhosis but hepatic steatosis noted on ultrasound 
imaging.  RN case manager or medical assistant will add hepatic steatosis information on 
patient’s clinic document, Hepatitis C Pretesting during health record preparation. 
 
4. Patient has office visit to the clinic with health history reviewed by DNP prepared nurse 
practitioner specialty provider for other liver disease, metabolic risk factors for NAFLD 
(diabetes, hyperlipidemia, obesity), and patient assessed for potential alcohol abuse past six 
months: 
a. Positive for men: more than 3 drinks per day and 21 drinks per week (Chalasani, 
2012) 
b. Positive for women: more than 2 drinks per day and 14 drinks per week (Chalasani, 
2012) 
 
5. Negative findings for diagnosis differentials for hepatic steatosis and negative for alcohol 
abuse leading to diagnosis of NAFLD by DNP prepared nurse practitioner specialty provider.  
NAFLD fibrosis score calculated. 
 
6. Patient’s health record includes notation of NAFLD diagnosis on clinic document, Hepatitis 
C Treatment Flow Sheet and calculated NAFLD fibrosis score (Angulo, et al., 2007) added 
to clinic document, Hepatitis C Pretesting. 
 
7. Patient has second office visit to the clinic to discuss hepatitis C treatment and signs clinic’s 
document, Hepatitis C Therapy Treatment Agreement.  Treatment of hepatitis C infection 
according to evidence based guidelines by the American Association for the Study of Liver 
Diseases (AASLD), Infectious Diseases Society of America (IDSA), and International 
Antiviral Society–USA (IAS–USA). 
  
8. Patient’s health record is flagged with NAFLD green sticker on the Hepatitis C Clinic 
document, Lab Requisition and Appointment to remind the DNP prepared nurse practitioner 
discharge letter with NAFLD algorithms needs to be sent to PCP at end of treatment 
(coincides with lab draw date). 
 
9. Last office visit at the clinic with the DNP prepared nurse practitioner is two weeks before 
end of treatment.  At this visit, patient diagnosed with NAFLD receives education on 
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NAFLD and instructions to follow up with PCP after discharge from the clinic.  Teach-back 
method used to assess patient understanding of information/education. Completion of 
education and teach-back noted on Hepatitis C Treatment Flow Sheet.  The DNP prepared 
nurse practitioner dictation of office visit encounter sent to PCP will include new NAFLD 
diagnosis information.   
 
10. Two weeks after patient’s last office visit and completion of treatment, the discharge letter 
and algorithms for transition of care from DNP prepared nurse practitioner to PCP is mailed, 
this is documented on the Hepatitis C Treatment Flow Sheet. 
 
11. The DNP student will contact the PCP’s office clinical staff two weeks after patient 
discharge letter and NAFLD algorithms are sent, to inform them a letter with a 
questionnaire is being faxed to the provider to answer for evaluation of the transition 
process from the clinic to the PCP for continuation of NAFLD treatment.  A clinic fax cover 
sheet will be used to fax to the PCP office and for return of the questionnaire by fax to the 
clinic. 
 
 Did you receive the patient’s discharge letter from the clinic provider noting 
diagnosis of nonalcoholic fatty liver disease (NAFLD)?                                                      
Yes _______    No _________ 
 Was the diagnosis of NAFLD added to the patient’s medical history or problem list?   
Yes _______    No ________ 
 Did you receive the NAFLD algorithm sent with the discharge letter from the Mercy 
Health Hepatitis C Clinic provider?    Yes ________    No _________ 
 Was the algorithm beneficial for the treatment/management of NAFLD?                  
Yes ______   No ________     
 Are there any suggestions for improvement of the process for transition of care from 
specialty care to primary care for the continuation of treatment for NAFLD?  
 
12.  A follow up phone call will be made to the referring PCP clinical staff by the DNP student 
if the questionnaire is not returned in seven days to the clinic in care of the DNP prepared 
nurse practitioner specialty provider. 
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Appendix I 
 
Diagram of Protocol for Patient Referral to Hepatitis C Clinic with Hepatic Steatosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referral to Hepatitis C 
Clinic for treatment 
hepatitis C
Review of referral 
required documents 
from primary care 
provider (PCP)
Imaging RUQ negative 
for cirrhosis but positive  
hepatitic steatosis
Patient office visit with 
DNP with review of 
health history and 
referral documents
Negative for 
differentials of hepatic 
steatosis and negative 
for alcohol abuse
Patient preparation for 
start of hepatitis C 
treatment only but has 
NAFLD
Treatment of  hepatitis 
C according to evidence 
based guidelines
At the last office visit -
NAFLD patient 
education and follow up 
instructions
Discharge letter to PCP 
from NP with NAFLD 
management algorithm 
at the end of treatment
Questionnaire faxed to 
referring PCP 2 weeks 
after treatment 
completed
Follow up phone call to 
PCP clinical staff if 
questionnaire not 
returned
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Appendix J 
 
 Discharge Letter from Specialty to Primary Care Provider 
 
Date 
Primary Care Provider Name 
Address 
Address  
Dear Primary Care Provider: 
Name (birthdate) has been under our care and has completed treatment of his/her hepatitis C 
which was started in month/year.  He/she completed number weeks of treatment with name of 
drug(s).   I will order a HCV RNA lab for your patient in three months to evaluate for a viral 
cure.   
Your patient was noted to have steatosis on radiologic imaging and meets criteria for 
nonalcoholic fatty liver disease (NAFLD).  The NAFLD diagnosis was included in my dictation 
sent to you after the patient’s last clinic visit.  The patient has received education on NAFLD and 
instructed to follow up with you for continuation of care and monitoring.   
NAFLD is a spectrum of liver disease that ranges from simple fatty infiltration of the liver 
(steatosis) to liver inflammation, nonalcoholic steatohepatitis (NASH).  NASH is the progressive 
form of NAFLD that can lead to cirrhosis, hepatocellular carcinoma necessitating liver 
transplantation and liver-related mortality.   
The American Association for the Study of Liver Diseases (AASLD), jointly with the American 
College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA), 
published guidelines in 2012 for the management of NAFLD and NASH.  The enclosed 
algorithm was developed to assist you with transition of care and management of NAFLD.  
Thank you for allowing me to participate in the care of this patient.  Please call the Hepatitis C 
Clinic if you have any additional questions. 
Hepatitis C Clinic Provider                                                                                                           
Hepatitis C Clinic Address                                                                                                                   
Phone Number                                                                                                                                               
Fax Number 
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Appendix K 
 
Radiological Imaging Algorithm for Hepatic Steatosis 
 
 
 
 
 
Imaging  Results  
Cirrhosis
Every 6 months AFP & 
liver labs and imaging
Negative 
Hepatic Steatosis
Hepatitis C Treatment hepatitis C
Positive alcohol abuse Stop alcohol 
Negative alcohol abuse
NAFLD (nonalcoholic 
fatty liver disease)
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Appendix L 
 
Nonalcoholic Fatty Liver Disease (NAFLD) Algorithm 
 
 
 
NAFLD
Diabetes
Standard Treatment  
Guideline
Hyperlipidemia
Standard Treatment 
Guideline 
Obesity 
Weight loss -
3-5% minimum
Standard Treatment 
Guidline
Monitoring
Vaccinations: Hepatitis 
A & B, pneumococcal 
and age appropriate   
Every 6 months lab 
CBC, platelet, protime, 
& liver enzymes
Liver Ultrasound for 
continued elevated 
liver enzymes
Refer to 
Gastroenterology for 
abnormal labs and or 
imaging
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Appendix M  
 
Nonalcoholic Fatty Liver Disease (NAFLD) Patient Education Handout 
Why is the liver important? 
The liver performs many jobs in your body.  It 
processes what you eat and drink into energy 
and nutrients your body can use.  The liver also 
removes harmful substances from your body.       
 
What is Nonalcoholic Fatty Liver Disease 
(NAFLD)? 
NAFLD is a name that is given to a range of 
liver conditions that are associated with the 
presence of too much fat in the liver. Some 
patients have a mild form of fatty liver. In 
other patients with fatty liver, inflammation of 
the liver may occur. This condition can lead to 
liver damage with scarring and cirrhosis. 
 
 
How Common is NAFLD? 
NAFLD is likely to occur in 27-34% of adults 
in the United States. With the current increase 
in obesity, these percentages continue to rise.  
The rate of NAFLD increases to 75-92% in 
adults who are grossly obese. 
 
What are the risk factors for NAFLD? 
 Obesity  
 Diabetes  
 Insulin resistance  
 High cholesterol  
      
 What are the symptoms of NAFLD? 
 Often there are no symptoms 
 When symptoms occur – most common 
o Fatigue 
o Pain or fullness in the upper 
right abdomen 
 Additional symptoms with liver 
inflammation 
o Weakness 
o Loss of appetite 
o Nausea 
o Yellow skin and eyes 
o Itching 
 
 
 
Treatment for NAFLD:  
 See your primary care provider for 
treatment & monitoring of NAFLD 
 Take medications for high blood 
pressure, diabetes and high 
cholesterol as directed by your 
primary care provider 
 Do not drink alcohol  
 Weight loss if you are overweight or 
obese (10 percent of current weight 
recommended) 
o Increase physical activity 
daily 
o Low calorie diet 
 Limit foods that are 
high in calories  
 Eat foods that have 
fiber (whole grains, 
fruit and vegetables) 
 
Additional Instructions/Goals: 
Follow up with your primary care provider 
after completion of hepatitis C treatment. 
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Appendix N 
 
Institutional Review Board Determination Letter-Grand Valley State University 
 
 
DATE: April 28, 2016 
TO: Debra Brown Bayus, MSN 
FROM: Grand Valley State University Human Research Review Committee 
STUDY TITLE: [901099-1] Identification of Nonalcoholic Fatty Liver Disease in Patients with 
Hepatitis C: Using Evidence Based Guidelines to Improve Diagnosis and 
Transition of Care from Specialty Care Provider to Primary Care Provider 
REFERENCE #: 
SUBMISSION TYPE: New Project 
ACTION: NOT RESEARCH EFFECTIVE 
DATE:  April 28, 2016 
REVIEW TYPE: Administrative Review 
Thank you for your submission of materials for your planned research study. It has been determined that this 
project: 
DOES NOT meet the definition of covered human subjects research* according to current federal regulations. 
The project, therefore, DOES NOT require further review and approval by the HRRC. 
If you have any questions, please contact the Research Protections Program at (616) 331-3197 or 
rpp@gvsu.edu. The office observes all university holidays, and does not process applications during exam 
week or between academic terms. Please include your study title and reference number in all correspondence 
with our office. 
*Research is a systematic investigation, including research development, testing and evaluation, designed to 
develop or contribute to generalizable knowledge (45 CFR 46.102 (d)). 
Human subject means a living individual about whom an investigator (whether professional or student) 
conducting research obtains: data through intervention or interaction with the individual, or identifiable private 
information (45 CFR 46.102 (f)). 
Scholarly activities that are not covered under the Code of Federal Regulations should not be described or 
referred to as research in materials to participants, sponsors or in dissemination of findings. 
Research Protections Program | 1 Campus Drive | 049 James H Zumberge Hall | Allendale, MI 49401                      
Phone 616.331.3197 | rpp@gvsu.edu | www.gvsu.edu/rpp 
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Appendix O 
 
PCP Letter Accompanying Questionnaire 
 
 
Date: 
 
Dear Primary Care Provider: 
 
Your patient has completed hepatitis C treatment and this communication is in regard to 
the transition of patient care to you for continuation of care for nonalcoholic fatty liver disease 
(NAFLD) diagnosed during treatment of hepatitis C.  Communication was previously sent to you 
regarding the patient and diagnosis requiring continuation of care.  It would be helpful if you 
could help with evaluating our process in transition of patient care from specialty care to primary 
care for continuation of care.  Please complete the attached questionnaire within seven days and 
fax back to the Hepatitis C Clinic.  A Hepatitis C Clinic fax cover sheet is also included for your 
convenience to fax the questionnaire back to the clinic.     
Thank you for your time and assistance. 
Hepatitis C Clinic Provider 
Address 
Phone Number 
Fax Number 
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Appendix P 
 
Hepatitis C Clinic Fax Cover Sheet to Send Questionnaire 
 
FAX 
Hepatitis C Clinic 
To:  From:    
Fax:  Fax:  XXX-XXX-XXXX  
Phone:  Phone:  XXX-XXX-XXXX 
Re:   Date:  
CC:  Pages:  
 Urgent  For Review  Please Comment  Please Reply  Please Recycle 
 
 
 
 
CONFIDENTIALITY NOTICE 
 
THE DOCUMENTS ACCOMPANYING THIS FAX TRANSMISSION CONTAIN CONFIDENTIAL 
INFORMATION, BELONGING TO THE SENDER, THAT IS LEGALLY PRIVILEGED.  THIS INFORMATION IS 
INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE.  THE AUTHORIZED 
RECIPIENT OF THIS INFORMATION IS PROHIBITED FROM DISCLOSING THIS INFORMATION TO ANY 
OTHER PARTY AND IS REQUIRED TO DESTROY THE INFORMATION AFTER ITS STATED NEED HAS 
BEEN FULFILLED, UNLESS OTHERWISE REQUIRED BY STATE LAW. 
 
IF YOU HAVE RECEIVED THIS FAX IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY OR 
CONTACT OUR CORPORATE COMPLIANCE OFFICE AT (XXX) XXX-XXXX 
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Appendix Q 
 
Hepatitis C Clinic Fax Cover Sheet for Return of Questionnaire 
 
FAX 
Hepatitis C Clinic 
To:  From:   
Fax: XXX-XXX-XXXX Fax:   
Phone: XXX-XXX-XXXX Phone:   
Re:   Date:  
CC:  Pages:  
 Urgent  For Review  Please Comment  Please Reply  Please Recycle 
 
 
 
 
CONFIDENTIALITY NOTICE 
 
THE DOCUMENTS ACCOMPANYING THIS FAX TRANSMISSION CONTAIN CONFIDENTIAL 
INFORMATION, BELONGING TO THE SENDER, THAT IS LEGALLY PRIVILEGED.  THIS INFORMATION IS 
INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE.  THE AUTHORIZED 
RECIPIENT OF THIS INFORMATION IS PROHIBITED FROM DISCLOSING THIS INFORMATION TO ANY 
OTHER PARTY AND IS REQUIRED TO DESTROY THE INFORMATION AFTER ITS STATED NEED HAS 
BEEN FULFILLED, UNLESS OTHERWISE REQUIRED BY STATE LAW. 
IF YOU HAVE RECEIVED THIS FAX IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY OR 
CONTACT OUR CORPORATE COMPLIANCE OFFICE AT (XXX) XXX-XXXX 
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Appendix R 
 
Revised Protocol Process for a Patient Referral to Hepatitis C Clinic with Hepatic Steatosis  
 
1. Referral received from primary care provider (PCP) to the clinic for treatment hepatitis C by 
registered nurse (RN) case manager or medical assistant. 
 
2. Review of referral patient’s required health history, labs and ultrasound of right upper 
quadrant (RUQ) by RN case manager or medical assistant and patient’s chart is prepared for 
the first clinic visit for hepatitis C treatment. 
 
3. Radiological imaging results are negative for cirrhosis but hepatic steatosis noted on 
radiological imaging.  RN case manager or medical assistant will add hepatic steatosis 
information on patient’s clinic document, Hepatitis C Pretesting during chart preparation 
and add green sticker to the patient’s chart. 
 
4. During the consultation visit, the patient has a Fibroscan performed by a clinic team 
member for hepatic steatosis and fibrosis.  The results are added to the patient’s health 
record and reviewed by the DNP prepared nurse practitioner.  
 
5. During the consultation visit, lab results the health history is reviewed by DNP prepared 
nurse practitioner specialty provider for other liver disease, metabolic risk factors for 
NAFLD (diabetes, hyperlipidemia, obesity), and patient assessed for potential alcohol abuse 
past six months: 
a. Positive for men: more than 3 drinks per day and 21 drinks per week (Chalasani, 
2012) 
b. Positive for women: more than 2 drinks per day and 14 drinks per week (Chalasani, 
2012) 
 
6. Positive finding for hepatic steatosis and negative for other differential diagnoses for hepatic 
steatosis, and negative for alcohol abuse leading to diagnosis of NAFLD by DNP prepared 
nurse practitioner specialty provider.  Patient diagnosed with NAFLD receive education on 
NAFLD and instructions to follow up with their PCP.  Teach-back method used to assess 
patient understanding of information/education. 
 
7. The patient’s health record includes notation of NAFLD diagnosis on clinic document, 
Hepatitis C Treatment Flow Sheet.  The DNP prepared nurse practitioner’s dictation of 
patient encounter sent to the PCP will include new NAFLD diagnosis information and 
completion of patient education with teach-back.   
 
8. The patient has second office visit to the clinic is to discuss hepatitis C treatment and signs 
Hepatitis C Clinic’s document, Hepatitis C Therapy Treatment Agreement.  Treatment of 
hepatitis C infection according to evidence based guidelines by the American Association 
for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA), 
and International Antiviral Society–USA (IAS–USA). 
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9. The last office visit at the clinic with the DNP prepared nurse practitioner is two weeks 
before end of treatment.  At this visit, patient diagnosed with NAFLD receives education on 
NAFLD again with instructions to follow up with PCP after discharge from the clinic.  
Teach-back method used to assess patient understanding of information/education. The 
DNP prepared nurse practitioner dictation of office visit encounter sent to the PCP will 
include NAFLD diagnosis information and follow up with PCP.   
 
10. The patient’s clinic document, Lab Requisition and Appointment is flagged with NAFLD 
green sticker to remind the DNP prepared nurse practitioner that discharge letter with 
NAFLD algorithm needs to be sent to PCP at end of treatment when lab results are available 
and reviewed. 
 
11. A copy of the discharge letter sent to the PCP from the clinic DNP prepared nurse 
practitioner is placed in patient’s health record. 
 
